Medivate Partners

Cipherome is a biotech company that finds the drug that works for each individual. Its company was founded on the belief that each individual deserves the best medicine. Serious side effects or adverse drug reactions (ADRs) occur in certain individuals, but not in others. These differences may be due to inherited factors. Its unique patented platform combines many components, including genetics, to provide the best drug for everyone.

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.

Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today.

WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The company leveraging its proprietary platform to develop a novel class of cell therapies called MILs (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow. WindMIL Therapeutics was established in 2015 and is based in Baltimore, MD.

Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today.

SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul South Korea and Financial District, San Francisco. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVE™ platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. 2003. Jennerex, Inc. (San Francisco, USA) was established. 2014. SillaJen acquires Jennerex, Inc. 2015. In April 2015. SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer. 2015. In October 2015, SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products." 2016. In January 2016, SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer. In December 2016. SillaJen is listed on KOSDAQ market in South Korea. 2017. In may 2017, Sillajen signs collaborative agreement with Regeneron Pharmaceuticals for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors. In July 2017, SillaJen received approval from the China CFDA to commence phase 3 clinical trial for Pexa-Vec in liver cancer. In Aug 2017, Sillajen signs collaborative agreement with the National Cancer Institute for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors.